Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
Open Access
- 10 October 2019
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-8
Abstract
Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study investigated the long term effects of IM in TGCT. We conducted an international multi-institutional retrospective study to assess the activity of IM: data was collected anonymously from individual patients with locally advanced, recurrent or metastatic TGCT. Sixty-two patients from 12 institutions across Europe, Australia and the United States were identified. Four patients with metastatic TGCT progressed rapidly on IM and were excluded for further analyses. Seventeen of 58 evaluable patients achieved complete response (CR) or partial response (PR). One- and five-year progression-free survival rates were 71% and 48%, respectively. Thirty-eight (66%) patients discontinued IM after a median of 7 (range 1–80) months. Reported adverse events in 45 (78%) patients were among other edema (48%) and fatigue (50%), mostly grade 1–2 (89%). Five patients experienced grade 3–4 toxicities. This study confirms, with additional follow-up, the efficacy of IM in TGCT. In responding cases we confirmed prolonged IM activity on TGCT symptoms even after discontinuation, but with high rates of treatment interruption and additional treatments.Keywords
This publication has 35 references indexed in Scilit:
- Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitisCancer, 2011
- Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitisCurrent Opinion in Oncology, 2011
- The safety profile of imatinib in CML and GIST: long-term considerationsArchives of Toxicology, 2011
- Malignant pigmented villonodular synovitis of the temporomandibular joint with lung metastasis: a case report and review of the literatureOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2011
- Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic reviewInternational Journal of Cancer, 2011
- Practical management of tyrosine kinase inhibitor-associated side effects in GISTCancer Treatment Reviews, 2011
- Stellenwert der externen Radiotherapie bei der adjuvanten Behandlung der pigmentierten villonodulären SynovitisZeitschrift für Orthopädie und Unfallchirurgie, 2011
- Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive SynovitidesAmerican Journal of Surgical Pathology, 2007
- Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitorsMolecular Cancer Therapeutics, 2006
- A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cellsProceedings of the National Academy of Sciences, 2006